

DAFTAR PUSTAKA

- Ababneh, M., Nasser, S. A., Rababa'h, A., & Ababneh, F. (2021). *Warfarin adherence and anticoagulation control in atrial fibrillation patients: a systematic review*. *European Review for Medical and Pharmacological Sciences*, 25(24), 7926–7933.
- Abdolmanafi, A., Duong, L., Dahdah, N., Adib, I. R., & Cheriet, F. (2018). *Characterization of coronary artery pathological formations from OCT imaging using deep learning*. *Biomedical Optics Express*, 9 10, 4936–4960.
- Al'Aref, S. J., Maliakal, G., Singh, *et al.* (2019). *Machine learning of clinical variables and coronary artery calcium scoring for the prediction of obstructive coronary artery disease on coronary computed tomography angiography: analysis from the CONFIRM registry*. *European Heart Journal*.
- Alberts, M., Chen, Y. W., Lin, *et al.* (2020). *Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin*. *Stroke*, 51(2), 549–555.
- Alshehri, A. M. (2019). *Stroke in atrial fibrillation: Review of risk stratification and preventive therapy*. In *Journal of Family and Community Medicine*, Vol. 26, Issue 2, pp. 92–97.
- Andrade, J. G., Aguilar, M., *et al.* (2020). *The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation and Members of the Secondary Panel*. *Canadian Journal of Cardiology*, 36, 1847–1948.
- Arnouk, S., Altshuler, D., Lewis, T. C., *et al.* (2020). *Evaluation of Anti-Xa and Activated Partial Thromboplastin Time Monitoring of Heparin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Support*. *ASAIO Journal* (American Society for Artificial Internal Organs : 1992), 66(3), 300–306.
- Ball, J. (2017). *Which anticoagulant for stroke prevention in atrial fibrillation?* *BMJ*, 359, j5399.
- Bratsos, S. (2019). *Pharmacokinetic Properties of Rivaroxaban in Healthy Human*

Subjects. <https://doi.org/10.7759/cureus.5484>

- Byon, W., Garonzik, S., Boyd, R. A., & Frost, C. E. (2019). *Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review*. *Clinical Pharmacokinetics*, 58(10), 1265–1279.
- Carnicelli, A. P., Hong, H., Connolly, S. J., *et al.* (2022). *Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex*. *Circulation*, 145(4), 242–255.
- Connolly, S. J., Karthikeyan, G., Ntsekhe, M., *et al.* (2022). *Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation*. *The New England Journal of Medicine*, 387(11), 978–988.
- Dorgalaleh, A., Favaloro, E. J., Bahraini, M., & Rad, F. (2021). *Standardization of Prothrombin Time/International Normalized Ratio (PT/INR)*. *International Journal of Laboratory Hematology*, 43(1), 21–28.
- Fralick, M., Colacci, M., Schneeweiss, S., Huybrechts, *et al.* (2020). *Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice a cohort study*. *Annals of Internal Medicine*, 172(7), 463–473.
- Giommi, A., *et al.* (2023). *Does the small conductance Ca^{2+} -activated K^{+} current (ISK) flow under physiological conditions in rabbit and human atrial isolated cardiomyocytes?*. *Journal of Molecular and Cellular Cardiology*, 183 (10)
- Healey, J. S., Lopes, R. D., Granger, C. B., *et al.* (2024). *Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation*. *New England Journal of Medicine*, 390(2), 107–117.
- Heijman, J., Luermans, J. G. L. M., Linz, D., *et al.* (2021). *Risk Factors for Atrial Fibrillation Progression*. In *Cardiac Electrophysiology Clinics* (Vol. 13, Issue 1, pp. 201–209).
- Hindricks, G., Potpara, T., Kirchhof, P., *et al.* (2021). *2020 ESC Guidelines for the*

- diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). In European Heart Journal (Vol. 42, Issue 5, pp. 373–498).*
- Hoffbrand, A. V. ., & Moss, P. A. H. (2016). *Hoffbrand's essential haematology*. <https://search.worldcat.org/title/910009732>
- Hu, P., Huang, J., Lu, Y., Zheng, M., Li, H., *et al.* (2022). *Circulating sex hormones and risk of atrial fibrillation: A systematic review and meta-analysis*. *Frontiers in Cardiovascular Medicine*, 9, 952430.
- Huang, Y. L., Chen, C. Y., *et al.* (2022). *Risk of major bleeding and thromboembolism in Asian patients with nonvalvular atrial fibrillation using direct oral anticoagulants versus warfarin*. *International Journal of Clinical Pharmacy*, 44(1), 34–43.
- IRAMA RSSA. (2019). <https://rsusaifulanwar.jatimprov.go.id/wp-content/uploads/2019/08/PROPOSAL-IRAMA-FINAL-ipjt.pdf>
- January, C. T., Wann, L. S., Alpert, J. S., *et al.* (2014). *2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of cardiology/American heart association task force on practice guidelines and the heart rhythm society*. *Circulation*, 130(23), 2071–2104.
- January, C. T., Wann, L. S., *et al.* (2019). *2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons*. *Circulation*, 140(2), e125–e151.
- Joglar, J. A., Chung, M. K., *et al.* (2024). *2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines*. *Journal of the American College of Cardiology*, 83(1), 109–279.

- Kirchhof, P., Benussi, S., *et al.* (2016). *2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS*. European Heart Journal, 37(38).
- Kirchhof, P., Benussi, S., *et al.* (2016). *2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS*. European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery, 50(5), E1–E88.
- Kjerpeseth Id, L. J., Selmer, R., *et al.* (2019). *Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study*. PloS ONE, 14(8), 8.
- Kornej, J., Börschel, C. S., *et al.* (2020). *Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights*. In *Circulation Research* (Vol. 127, Issue 1, pp. 4–20). Lippincott Williams and Wilkins.
- Kovacs, R. J., Flaker, G. C., *et al.* (2015). *Practical Management of Anticoagulation in Patients With Atrial Fibrillation*. Journal of the American College of Cardiology, 65(13), 1340–1360.
- Kustos, S., & Fasinu, P. (2019). *Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update*. Medicines (Basel, Switzerland), 6(4), 103.
- Levy, J. H., Szlam, F., Wolberg, A. S., & Winkler, A. (2014). *Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing*. Clinics in Laboratory Medicine, 34(3), 453–477.
- Li, H., Song, X., *et al.* (2022). *Global, regional, and national burden of disease study of atrial fibrillation/flutter, 1990–2019: results from a global burden of disease study, 2019*. BMC Public Health, 22(1), 2015.
- Lip, G. Y. H., Banerjee, A., *et al.* (2018). *Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report*. CHEST, 154(5), 1121–1201.
- Mende, J., Rahmawati, F., & Puspitasari, I. (2022). *Keamanan Penggunaan Antikoagulan pada Pasien Rawat Inap Stroke Iskemik dengan Atrial*

- Fibrilasi. *Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice)*, 12(3), 176.
- Misnah, M., Abdullah, A. A., Arif, M., & Bahar, B. (2016). Pemeriksaan *Prothrombin Time* dan *Activated Partial Thromboplastin Time* dengan Humaclof VA serta SYSMEX CA 500. *Indonesian Journal of Clinical Pathology and Medical Laboratory*, 18(3).
- Nattel, S., Heijman, J., Zhou, L., & Dobrev, D. (2020). *Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective*. In *Circulation Research* (Vol. 127, Issue 1, pp. 51–72).
- Nelson, A. J., & Alexander, J. H. (2019). *Anticoagulation-Related Major Bleeding in Patients With Atrial Fibrillation: Looking Behind the Curtain*. *Circulation*, 140(22), 1802–1804.
- Nesheiwat Z., Goyal A., & Jagtap M. (2023). *Atrial Fibrillation*. In *StatPearls [Internet]*. StatPearls Publishing.
<https://www.ncbi.nlm.nih.gov/books/NBK526072/>
- Ngolet, L., Ova, J. D. O. G., *et al.* (2017). *Bleeding feature in the Hematology department in Brazzaville, Congo*. <https://doi.org/10.15520/.V5I9.77>
- Paciaroni, M., Agnelli, G., *et al.* (2017). *Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with Non-Vitamin-K oral anticoagulants (RAF-NOACs) Study*. *Journal of the American Heart Association*, 6(12).
- Patel, S., Singh, R., Preuss, C. V., & Patel, N. (2024). *Warfarin*. *Hemostasis and Thrombosis: Fourth Edition*, 161–168.
- PERKI. (2014). *Pedoman Tata Laksana Fibrilasi Atrium*. Edisi 1. Jakarta : Centra Communications. PERKI. 2019. *Pedoman Tata Laksana Fibrilasi Atrium Nonvalvular*. Edisi 2. Jakarta : PT. Trans Medical International.
- PERKI. (2019). *Pedoman Tata Laksana Fibrilasi Atrium Nonvalvular*. Edisi 2. Jakarta : PT. Trans Medical International.
- Pinzon, R. T., Astyari, G. A. P. I. B. S., & Taringan, L. (2017). Antitrombotik berdasarkan skor CHA2DS2-VASc dan skor HAS BLED terhadap pola

- pengobatan pada pasien stroke iskemik dengan fibrilasi atrium. *Pharmaciana*, 7(1), 63.
- Piran, S., & Schulman, S. (2019). *Review Series New Therapeutics for Inherited and Acquired Bleeding Conditions: Treatment of bleeding complications in patients on anticoagulant therapy*. *Blood*, 133(5), 1.
- Piran, S., & Schulman, S. (2019). *Treatment of bleeding complications in patients on anticoagulant therapy*. *Blood*, 133(5), 425–435.
- San San Tan, C., Wen Huey Lee, S., *et al.* (2021). *Warfarin and food, herbal or dietary supplement interactions: A systematic review*. *British Journal of Clinical Pharmacology*, 87(2), 352–374.
- Senoo, K., Proietti, M., Lane, D. A., & Lip, G. Y. H. (2016). *Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin*. *The American Journal of Medicine*, 129(6), 600–607.
- Steffel, J., Collins, R., *et al.* (2021). *2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation*. *Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology*, 23(10), 1612–1676.
- Tan, C. S. S., & Lee, S. W. H. (2021). *Warfarin and food, herbal or dietary supplement interactions: A systematic review*. *British Journal of Clinical Pharmacology*, 87(2), 352–374.
- Thompson, A. E. (2015). *Atrial fibrillation*. *JAMA*, 313(10), 1070. <https://doi.org/10.1001/JAMA.2015.1337>
- Tzeis, S., Gerstenfeld, E. P., *et al.* (2024). *2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation*. *Europace*, 26(4).

- Tzeis, S., Gerstenfeld, E. P., *et al.* (2024). *2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation*. *Europace*, 26(4).
- Van Gelder, I. C., Rienstra, M., Crijns, H. J. G. M., & Olshansky, B. (2016). *Rate control in atrial fibrillation*. *Lancet* (London, England), 388(10046), 818–828.
- Vig, S., Chitolie, A., Bevan, D., *et al.* (2023). *Thromboelastography*. *Hematology*, 6(3), 205–213.
- Vimalesvaran, K., Dockrill, S. J., & Gorog, D. A. (2018). *Vascular Health and Risk Management Dovepress Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice*. *Vascular Health and Risk Management*, 14–27.
- Wang, C. L., Wu, V. C. C., *et al.* (2019). *Safety and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study*. *Journal of the American Heart Association*, 8(9).
- Yao, X., Abraham, N. S., *et al.* (2016). *Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation*. *Journal of the American Heart Association*, 5(6).
- Yuan, Y., Li, X., & Qiu, F. (2023). *Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis*. *Clinical and Applied Thrombosis/Hemostasis*, 29.